News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting



12/12/2011 11:10:23 AM

BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics, Inc., announced today the presentation of clinical and preclinical data for AVL-292, a highly selective Bruton’s tyrosine kinase (Btk) inhibitor, at the 2011 American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, CA. Avila presented data on the safety and pharmacology of AVL-292 from the first two patient cohorts from the ongoing Phase 1b clinical study of AVL-292 in B cell cancers.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES